Elmar Kraus
Stock Analyst at DZ Bank
(2.92)
# 1,544
Out of 4,754 analysts
12
Total ratings
80%
Success rate
25.75%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Elmar Kraus
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LLY Eli Lilly and Company | Downgrades: Hold | $820 | $929.72 | -11.80% | 4 | Feb 21, 2024 | |
| GSK GSK plc | Downgrades: Hold | n/a | $37.95 | - | 1 | Feb 11, 2022 | |
| AZN AstraZeneca | Upgrades: Hold | n/a | $76.10 | - | 1 | Feb 11, 2022 | |
| PFE Pfizer | Upgrades: Buy | $41 | $26.25 | +56.19% | 2 | Feb 4, 2021 | |
| MDT Medtronic | Downgrades: Hold | $92 | $94.30 | -2.44% | 2 | May 14, 2020 | |
| GILD Gilead Sciences | Upgrades: Buy | n/a | $115.99 | - | 2 | Mar 18, 2020 |
Eli Lilly and Company
Feb 21, 2024
Downgrades: Hold
Price Target: $820
Current: $929.72
Upside: -11.80%
GSK plc
Feb 11, 2022
Downgrades: Hold
Price Target: n/a
Current: $37.95
Upside: -
AstraZeneca
Feb 11, 2022
Upgrades: Hold
Price Target: n/a
Current: $76.10
Upside: -
Pfizer
Feb 4, 2021
Upgrades: Buy
Price Target: $41
Current: $26.25
Upside: +56.19%
Medtronic
May 14, 2020
Downgrades: Hold
Price Target: $92
Current: $94.30
Upside: -2.44%
Gilead Sciences
Mar 18, 2020
Upgrades: Buy
Price Target: n/a
Current: $115.99
Upside: -